The monoclonal antibodies (mAbs) market has seen impressive growth in recent years, with the top-selling drugs increasingly being mAbs. The success of these therapeutics has driven the pharma industry to seek innovative methods for refining and improving their antibody pipelines. Artificial intelligence (AI) and deep learning, which have already revolutionized small molecule drug design, are now making significant strides in the development and optimization of antibodies.
This content available exclusively for BPT Mebmers
Topics: Biotech Companies